NCT03544255

Drug Screening of Pancreatic Cancer Organoids Developed From EUS-FNA Guided Biopsy Tissues

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: Ying Lv · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

We are going to establish "organoid" models from pancreatic cancer biopsies achieved via EUS-FNA. Then the sensitivity of the selected FDA-approved anti-cancer drugs will be tested in these organoids.

Detailed description

The survival rate of pancreatic cancer, a kind of malignant tumor, remains poor due to lack of effective treatments. Recently, a new model called "organoid" has been generated from human and murine pancreatic cancer tissues. These organoids are developed from large pieces of surgical tissues or small biopsies taken from EUS-FNA guided samples. Here in our study we are going to establish "organoid" models from pancreatic cancer biopsies achieved via EUS-FNA. After successful generation of these organoids, we will treat them with the selected FDA-approved anti-cancer drugs, and assess the responses to these anti-cancer agents in our established organoids.

Conditions

• Pancreatic Cancer
• Pancreas Adenocarcinoma

Interventions

Type	Name	Description
PROCEDURE	Biopsy	Two extra EUS-FNA guided pancreatic biopsies collected for only research purposes.

Timeline

• Start date: 2018-05-01
• Primary completion: 2020-12-01
• Completion: 2021-06-01
• First posted: 2018-06-01
• Last updated: 2020-01-07

Locations

1 site across 1 country: China